The role of the fixed-combination drugs in glaucoma treatment. Fixed-combination drugs versus monotherapy

Article Sidebar

PDF (Język Polski)


Published: Mar 31, 2016
Keywords:
glaucoma, target intraocular pressure, persistance, adherence, fixed-combination therapy

Main Article Content

Małgorzata Karolczak-Kulesza
Katedra Okulistyki i Klinika Okulistyczna, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
Sonia Pecold-Zielińska
Katedra Okulistyki i Klinika Okulistyczna, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
Jarosław Kocięcki
Katedra Okulistyki i Klinika Okulistyczna, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Abstract

Glaucoma affects millions of individuals. This disease is one of the leading causes of blindness. Elevated intraocular pressure often associates with glaucoma progression. Nowadays, there are lots of therapeutic methods of glaucoma treatment, but topical therapy remains first choice treatment. In this article, the authors present how important role is multiple medications in the treatment of patients, when monotherapy is ineffective and insufficient in intraocular pressure reduction. The advantages of fixed-combination drugs – their effectiveness, tolerability, influence on chronic persistence and adherence have been analyzed. The attention was drawn to one of the novel fixed-combination drug (brimonidine + brinzolamide), the only one without β-blocker. It is really important for patients, for whom timolol therapy is contraindicated.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Karolczak-Kulesza M, Pecold-Zielińska S, Kocięcki J. The role of the fixed-combination drugs in glaucoma treatment. Fixed-combination drugs versus monotherapy. Ophthatherapy [Internet]. 2016Mar.31 [cited 2024Jul.3];3(1):13-7. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/588
Issue
Vol 3 No 1 (2016)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90: 262-7.
2. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2008; 130(4): 429-40.
3. European Glaucoma Society. Terminology and guidelines for glaucoma. 4th edition. Publicomm, Savona, Italy 2014: 134-60.
4. Inoue K. Managing adverse effects of glaucoma medications. Clin Ophthalmol. 2014; 8: 903-13.
5. Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertensive Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120(6): 701-13.
6. Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systemic review. Patient Prefer Adherence. 2011; 5: 441-63.
7. Nordstrom BL, Friedman DS, Mozaffari E et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005; 140(4): 598-606.
8. Nguyen QH. Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Prefer Adherence. 2014; 8: 853-64.
9. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005; 112(5): 863-8.
10. Buller A, Hercules BL. Should patients choose their own eyedrops? Acta Ophthalmol Scand. 2006; 84(1): 150-1.
11. Schwartz G, Burk C, Bennett T et al. Adherence and persistence with glaucoma therapy: brimonidine/timolol versus dorzolamide/timolol and various two-bottle combinations. J Clin Exp Ophthalmol. 2012; 3(8): 1-6.
12. Inoue K, Okayama R, Higa R et al. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination. J Ocul Pharmacol Ther. 2011; 27(6): 581-7.
13. Greig SL, Deeks ED. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension. Drugs Aging. 2015; 32: 251-60.
14. Aung T, Laganovska G, Hernandez Paredes TJ et al. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology. 2014; 121: 2348-55.
15. Gandolfi SA, Lim J, Sanseau AC et al. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open angle glaucoma or ocular hypertension. Adv Ther. 2014; 31: 1213-27.
16. Nakano T, Mizoue S, Fuse N et al. Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: a prospective multicenter open-label study. Adv Ther. 2015; 32: 823-37.
17. Cheng JW, Cheng SW, Gao LD et al. Intraocular pressure-lowering effects of commonly used fixed combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012; 7(9): 1-11.
18. Misiuk-Hojło M, Pyziak A. Kluczowe aspekty decydujące o wyborze leku złożonego w terapii neuropatii jaskrowej – teoria i praktyka. OphthaTherapy. 2015; Suplement 1: 9-14.
19. Holló G, Vuorinen J, Tuominen J et al. Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014; 31: 932-44.